Corcept Therapeutics (CORT) Receivables - Net (2016 - 2025)
Corcept Therapeutics (CORT) has disclosed Receivables - Net for 14 consecutive years, with $59.8 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 10.76% to $59.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.8 million through Dec 2025, up 10.76% year-over-year, with the annual reading at $59.8 million for FY2025, 10.76% up from the prior year.
- Receivables - Net hit $59.8 million in Q4 2025 for Corcept Therapeutics, down from $69.6 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $69.6 million in Q3 2025 to a low of $22.2 million in Q1 2021.
- Historically, Receivables - Net has averaged $42.3 million across 5 years, with a median of $33.6 million in 2023.
- Biggest five-year swings in Receivables - Net: decreased 16.8% in 2021 and later skyrocketed 88.95% in 2024.
- Year by year, Receivables - Net stood at $27.6 million in 2021, then grew by 12.42% to $31.1 million in 2022, then skyrocketed by 32.41% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then grew by 10.76% to $59.8 million in 2025.
- Business Quant data shows Receivables - Net for CORT at $59.8 million in Q4 2025, $69.6 million in Q3 2025, and $64.6 million in Q2 2025.